Scribe Therapeutics files for Nasdaq IPO to test appetite for early-stage biotech
Scribe Therapeutics filed for a Nasdaq IPO to gauge investor appetite for early-stage biotech and gene-editing startups, backed by major investors including RA Capital, Andreessen Horowitz, OrbiMed and Avoro Capital.